Scholarlink

<p>Remote ischemic conditioning (RIC) has demonstrated neuroprotective effects, yet translating these effects into clinical efficacy has proven challenging. This study aims to uncover the molecular mechanisms underlying RIC’s protective effects, which could potentially identify new therapeutic targets. We conducted the ENOS pilot study, a patient-assessor blinded, Sham-controlled clinical trial, to investigate the molecular changes in patients diagnosed with acute ischemic stroke (AIS). Patients were assigned to undergo either RIC (<i>n</i> = 9), involving five cycles of transient ischemia and reperfusion of the arm, or a Sham treatment (<i>n</i> = 9), using a similar device with less pressure to avoid creating ischemia, within 48&#xa0;h of symptom onset. We collected plasma samples at three time points: at inclusion (pre-RIC), two hours post-initial RIC, and after seven days, with RIC administered twice daily. Analysis focused on brain biomarkers, specifically extracellular vesicle (EV) surface markers and circulating microRNAs (miRNAs). We identified significant differences in the regulation of CD62 on EVs and five specific miRNAs (miR-374a-5p, miR-20a-5p + miR-20b-5p, miR-19b-3p, miR-24-3p, miR-30d-5p) between the RIC and Sham groups. Notably, miR-374a-5p, known for its neuroprotective properties, was significantly increased in patients treated with RIC (<i>p</i> = 0.015). Furthermore, the changes of several of these miRNAs were correlated with improvements in red blood cell (RBC) deformability and aggregation during shear stress. In addition, we observed significant increases in CD62 on EVs at both the two-hour and 7-day follow-ups in the RIC group. These findings suggest that RIC may induce specific changes in EV surface markers and circulating miRNAs which could serve as future biomarkers for the RIC response. The trial was registered on clinicaltrails.gov (NCT04266639) on February 12, 2020 before trial initation on July 29, 2020.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring extracellular vesicle surface markers and microRNA regulation following remote ischemic conditioning in patients with stroke; a randomized-controlled pilot study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Rebecca Best Jensen,
  • Maria Kjølhede,
  • Jesper Just,
  • Lee-Ann Clegg,
  • Rikke Baek,
  • Erik Kaadt,
  • Betina Elfving,
  • David C. Hess,
  • Grethe Andersen,
  • Malene Møller Jørgensen,
  • Rolf Ankerlund Blauenfeldt,
  • Kim Ryun Drasbek

摘要

Remote ischemic conditioning (RIC) has demonstrated neuroprotective effects, yet translating these effects into clinical efficacy has proven challenging. This study aims to uncover the molecular mechanisms underlying RIC’s protective effects, which could potentially identify new therapeutic targets. We conducted the ENOS pilot study, a patient-assessor blinded, Sham-controlled clinical trial, to investigate the molecular changes in patients diagnosed with acute ischemic stroke (AIS). Patients were assigned to undergo either RIC (n = 9), involving five cycles of transient ischemia and reperfusion of the arm, or a Sham treatment (n = 9), using a similar device with less pressure to avoid creating ischemia, within 48 h of symptom onset. We collected plasma samples at three time points: at inclusion (pre-RIC), two hours post-initial RIC, and after seven days, with RIC administered twice daily. Analysis focused on brain biomarkers, specifically extracellular vesicle (EV) surface markers and circulating microRNAs (miRNAs). We identified significant differences in the regulation of CD62 on EVs and five specific miRNAs (miR-374a-5p, miR-20a-5p + miR-20b-5p, miR-19b-3p, miR-24-3p, miR-30d-5p) between the RIC and Sham groups. Notably, miR-374a-5p, known for its neuroprotective properties, was significantly increased in patients treated with RIC (p = 0.015). Furthermore, the changes of several of these miRNAs were correlated with improvements in red blood cell (RBC) deformability and aggregation during shear stress. In addition, we observed significant increases in CD62 on EVs at both the two-hour and 7-day follow-ups in the RIC group. These findings suggest that RIC may induce specific changes in EV surface markers and circulating miRNAs which could serve as future biomarkers for the RIC response. The trial was registered on clinicaltrails.gov (NCT04266639) on February 12, 2020 before trial initation on July 29, 2020.